Measuring heart blood flow with SPECT/CT scans in people with coronary artery disease
Compares SPECT/CT heart scans with PET scans in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: Quantitative Myocardial Perfusion Imaging Assessment by SPECT/CT
Key facts
- Where
- ORLEANS, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate coronary artery disease, or with lesions needing heart function imaging, who are referred for a SPECT or PET heart scan.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Moderate coronary atherosclerosis without significant narrowing (less than 50% stenosis), or coronary lesions for which heart function imaging or medical therapy is indicated, found on coronary CT angiography or invasive coronary angiography.
- Earlier treatment
- No earlier coronary revascularization (PCI, coronary stent or CABG).
Main reasons for not taking part
- Severe coronary disease needing prompt PCI or CABG, including left main stenosis over 50% or FFR below 0.80
- Earlier coronary revascularization (PCI, stent or CABG)
- Left ventricular ejection fraction below 35%
- Cannot have pharmacological stress testing, for example severe low blood pressure, second- or third-degree AV block or recent heart attack
- Pregnant or breastfeeding women
Read by machine on 13 November 2026.
Where in France
- Centre Hospitalier Universitaire d'OrléansORLEANS, FranceContact: Matthieu BAILLY, ProfessorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Régional d'Orléans
- Trial code
- NCT07708805
- Record updated
- 13 October 2026
- Original description
Myocardial perfusion single-photon emission computed tomography (SPECT) is a well-established functional imaging technique for the assessment of coronary artery disease. Recent developments in cadmium-zinc-telluride (CZT) camera technology have enabled significant reductions in acquisition time while improving image quality. Positron emission tomography (PET) myocardial imaging remains the reference standard for the quantitative assessment of myocardial blood flow (MBF) and myocardial flow reserve (MFR); however, its use is limited by high costs and restricted availability.Read full original descriptionShow less
Quantitative Myocardial Perfusion Imaging Assessment by SPECT/CT: Evaluation of Standardized Uptake Value (SUV) and Correlation With Myocardial Flow Reserve (MFR) Assessed by PET/CT
Myocardial perfusion single-photon emission computed tomography (SPECT) is a well-established functional imaging technique for the assessment of coronary artery disease. Recent developments in cadmium-zinc-telluride (CZT) camera technology have enabled significant reductions in acquisition time while improving image quality. Positron emission tomography (PET) myocardial imaging remains the reference standard for the quantitative assessment of myocardial blood flow (MBF) and myocardial flow reserve (MFR); however, its use is limited by high costs and restricted availability.
This exploratory study aims to evaluate the feasibility of using CZT-SPECT/CT imaging as an alternative approach by assessing the absolute quantification of myocardial tracer uptake, expressed as standardized uptake values (SUV), both at rest and during stress. The primary objective is to compare the ratio of stress-to-rest SUV obtained from SPECT with MFR values measured using PET imaging.
Patients under cardiology care at the University Hospital of Orléans who are scheduled for diagnostic coronary angiography or coronary CT angiography will be invited to participate. The study procedures will be integrated into their routine clinical workflow. On Day 0, participants will undergo a PET myocardial perfusion study using Rubidium-82, including measurement of MBF and MFR, with concomitant administration of 99mTc-tetrofosmin under pharmacological stress using the same vasodilator agent. A stress CZT-SPECT/CT acquisition will then be performed immediately after the PET scan. Within seven days of the initial evaluation, participants will undergo a rest CZT-SPECT/CT acquisition. Quantitative analysis of myocardial tracer uptake will subsequently be performed to derive SUV values.
The overall goal of this feasibility study is to generate preliminary data to support the design of a larger-scale clinical study. Ultimately, the study seeks to determine whether standard CZT-SPECT/CT imaging could provide a simpler, faster, and more widely accessible alternative to PET myocardial perfusion imaging for functional myocardial assessment.
Inclusion: Participant has provided informed consent to participate in the study; Age ≥ 18 years; Patients referred for functional cardiac imaging assessment (SPECT or PET) following diagnostic coronary CT angiography (CCTA) or invasive coronary angiography demonstrating either:; moderate coronary atherosclerosis without significant coronary stenosis (<50% stenosis), or; coronary lesions for which functional cardiac imaging assessment or medical therapy is indicated.
Exclusion: Severe coronary artery disease requiring prompt revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), including left main coronary artery stenosis >50% or other severe coronary lesions with FFR <0.80; History of coronary revascularization (PCI, coronary stenting, or CABG); Contraindication to pharmacological stress testing for cardiac PET/SPECT, including severe hypotension, second- or third-degree atrioventricular block, or recent myocardial infarction; Left ventricular ejection fraction (LVEF) <35%; Protected adult under legal guardianship or curatorship; Individual under judicial protection measures; Individual deprived of liberty; Individual not affiliated with a health insurance; Pregnant or breastfeeding woman.